Table 3.

Mutations with unknown effect on TKI therapy, choice of TKI, and molecular response observed.

Patient number	Mutation detected	TKI choice	Molecular responsea
2	Q300*	Imatinib	Good
7	D363_R386del	Nilotinib	Poor
15	V260G	Imatinib	Undetermined/static
24	V304RfsTer14	Imatinib	Undetermined
30	K219R	Nilotinib	Good
32	A412S	Imatinib	Good
44	E275Kb	Nilotinib	Poor
		Dasatinib	Good
70	G259D	Imatinib	Undetermined
81	A399T	Nilotinib	Good
89	I242V	Imatinib	Poor
91	A399T	Imatinib	Undetermined
93	I293N	Imatinib	Good
	N331D	Imatinib	Good
94	V260M	Nilotinib	Good
	E282V	Nilotinib	Good
96	V280M	Imatinib	Good
99	H396Y	Imatinib	Good
100	A399T	Imatinib	Poor
102	V339M	Imatinib	Undetermined
105	G254R	Dasatinib	Good
113	Y312C	Nilotinib	Good
142	R307N	Imatinib	Good
170	C330R	Nilotinib	Poor
195	L248Vc	Dasatinib	Undetermined
	L248_L247del	Dasatinib	Undetermined
198	V225F	Imatinib	Good
199	P367Q	Dasatinib	Undetermined
204	A399T	Nilotinib	Good
205	V260Ad	Nilotinib	Poor

Abbreviation: TKI, tyrosine kinase inhibitor.

Predicted responses:

^a Molecular responses were assessed according to the current European LeukemiaNet and National Comprehensive Cancer Network defined response criteria—using the same response milestones as for first‐line treatment. ³ , ⁷

^b Imatinib—resistant, Nilotinib—sensitive, Dasatinib—unknown.

^c Imatinib—resistant, Nilotinib—sensitive, Dasatinib—unknown.

^d Imatinib—resistant, Nilotinib—unknown, Dasatinib—unknown.